米拉贝隆
Mirabegron.
作者信息
Goulooze Sebastiaan C, Cohen Adam F, Rissmann Robert
机构信息
Centre for Human Drug Research, Leiden, The Netherlands.
Leiden University, Medical Center, Leiden, The Netherlands.
出版信息
Br J Clin Pharmacol. 2015 Oct;80(4):762-4. doi: 10.1111/bcp.12647. Epub 2015 Jun 5.
Abstract
Mirabegron is used for the treatment of symptoms associated with overactive bladder syndrome. It selectively stimulates the β3 -adrenoreceptor, which relaxes the detrusor muscle. This improves urine storage by distension of the bladder body.
摘要
米拉贝隆用于治疗膀胱过度活动症相关症状。它选择性地刺激β3肾上腺素能受体，使逼尿肌松弛。这通过膀胱体的扩张改善尿液储存。
相似文献
1
Mirabegron.米拉贝隆
Br J Clin Pharmacol. 2015 Oct;80(4):762-4. doi: 10.1111/bcp.12647. Epub 2015 Jun 5.
2
Mirabegron for overactive bladder.米拉贝隆用于治疗膀胱过度活动症。
Nurse Pract. 2012 Dec 10;37(12):9-10. doi: 10.1097/01.NPR.0000422213.00175.5d.
3
Mirabegron (Myrbetriq) for overactive bladder.米拉贝隆（贝坦利）用于治疗膀胱过度活动症。
Med Lett Drugs Ther. 2013 Feb 18;55(1410):13-5.
4
Mirabegron for the treatment of overactive bladder.米拉贝隆用于治疗膀胱过度活动症。
Drugs Today (Barc). 2012 Jan;48(1):25-32. doi: 10.1358/dot.2012.48.1.1738056.
5
The novel β3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity.新型 β3-肾上腺素能受体激动剂米拉贝隆可降低伴有或不伴有逼尿肌过度活动的膀胱出口梗阻患者膀胱组织中乙酰胆碱诱导的收缩活性。
Eur J Pharmacol. 2013 Jan 15;699(1-3):101-5. doi: 10.1016/j.ejphar.2012.11.060. Epub 2012 Dec 12.
6
[Pharmacological and clinical profile of mirabegron (Betanis(®)): a new therapeutic agent for overactive bladder].米拉贝隆（贝坦利（®））的药理与临床概况：一种治疗膀胱过度活动症的新型治疗药物
Nihon Yakurigaku Zasshi. 2012 May;139(5):219-25. doi: 10.1254/fpj.139.219.
7
A drug safety evaluation of mirabegron in the management of overactive bladder.米拉贝隆用于治疗膀胱过度活动症的药物安全性评估。
Expert Opin Drug Saf. 2016 May;15(5):689-96. doi: 10.1517/14740338.2016.1165663. Epub 2016 Apr 21.
8
Re: The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.回复：β3肾上腺素能受体激动剂米拉贝隆治疗老年患者膀胱过度活动症症状的疗效和耐受性
J Urol. 2015 Mar;193(3):947. doi: 10.1016/j.juro.2014.12.072. Epub 2014 Dec 18.
9
Drug therapy for an overactive bladder.膀胱过度活动症的药物治疗。
Womens Health (Lond). 2015 Jul;11(4):445-8. doi: 10.2217/whe.15.31. Epub 2015 Aug 4.
10
Combined treatment with a β -adrenergic receptor agonist and a muscarinic receptor antagonist inhibits detrusor overactivity induced by cold stress in spontaneously hypertensive rats.β-肾上腺素能受体激动剂与毒蕈碱受体拮抗剂联合治疗可抑制自发性高血压大鼠冷应激诱导的逼尿肌过度活动。
Neurourol Urodyn. 2017 Apr;36(4):1026-1033. doi: 10.1002/nau.23061. Epub 2016 Jul 1.
引用本文的文献
1
Effects of mirabegron on brown adipose tissue and metabolism in humans: A systematic review and meta-analysis.米拉贝隆对人体棕色脂肪组织和代谢的影响：系统评价和荟萃分析。
Eur J Clin Pharmacol. 2024 Mar;80(3):317-333. doi: 10.1007/s00228-023-03614-0. Epub 2023 Dec 30.
本文引用的文献
1
The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials.米拉贝隆对膀胱过度活动症患者相关结局的影响：使用三项随机III期试验的汇总数据进行事后相关性分析和应答者分析的结果
Qual Life Res. 2015 Jul;24(7):1719-27. doi: 10.1007/s11136-014-0904-4. Epub 2015 Feb 17.
2
Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials.基于基线时尿失禁严重程度的 β3-肾上腺素能受体激动剂米拉贝隆治疗膀胱过度活动症的疗效：三项随机 3 期临床试验汇总数据的事后分析。
Eur Urol. 2015 Jan;67(1):11-14. doi: 10.1016/j.eururo.2014.06.052. Epub 2014 Aug 2.
3
Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.米拉贝隆治疗膀胱过度活动症：疗效、安全性和耐受性评价。
Neurourol Urodyn. 2014 Jan;33(1):17-30. doi: 10.1002/nau.22505. Epub 2013 Oct 11.
4
Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome.β3 肾上腺素能受体激动剂在治疗膀胱过度活动症的临床开发中的药理学特性。
Naunyn Schmiedebergs Arch Pharmacol. 2013 Mar;386(3):177-83. doi: 10.1007/s00210-012-0824-1. Epub 2012 Dec 21.
5
Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors.毒蕈碱受体和β-肾上腺素能受体调控膀胱平滑肌张力的信号转导
Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):449-62. doi: 10.1007/s00210-007-0208-0. Epub 2007 Dec 4.
6
Neurophysiology of lower urinary tract function and dysfunction.下尿路功能及功能障碍的神经生理学
Rev Urol. 2003;5 Suppl 8(Suppl 8):S3-S10.
7
Defining overactive bladder: epidemiology and burden of disease.膀胱过度活动症的定义：流行病学与疾病负担
Urology. 2004 Dec;64(6 Suppl 1):2-6. doi: 10.1016/j.urology.2004.10.047.
8
The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.下尿路功能术语标准化：国际尿控协会标准化小组委员会报告
Neurourol Urodyn. 2002;21(2):167-78. doi: 10.1002/nau.10052.
Zotero 插件